As the evolution of innovative technologies is happening in the field of research and medicine, molecular diagnostics is growing rapidly. United States molecular diagnostics market is projected to surpass US$ 9 billion by 2024. Molecular diagnostics system is one of the hopeful systems that enable automation of extraction of high-quality nucleic acids from a wide variety of sample types and the selection of targeted, individualized treatment options. Molecular diagnostics system offers early disease detection, potentially before symptoms have even occurred.

In this report United States molecular diagnostics market has been segmented into three major categories: Oncology Test, Infectious Disease Test and Genetic Disease Test. Further, Oncology Test has been segmented into four major categories: Breast Cancer Test, Colorectal Cancer Test, Prostate Cancer Test and Other Cancer Test. Infectious Disease Test has been segmented into four major categories, namely, Virology, HAI, HPV and Critical Care Test and Genetic Test has been segmented into Blood Screening, HLA and Food Pathogen Test.

United State Molecular Diagnostics Market Shares: Overview

Our study found that both the Oncology and Infectious Test market have significant market in United States Molecular Diagnostics Market. In Molecular Oncology Test market; Breast cancer dominates the market on the other side in Molecular Infectious Test market; Virology is leading all other segments. While in terms of Tests Volume; Genetics test is leading all way ahead from Infectious and Oncology Test owing to Food Pathogen Test Volume.

The top players in United States Molecular Diagnostics Market includes several familiar names such as Roche, Hologic, Becton Dickinson, Myraid Genetics, Qiagen and Abbott, Siemens, bioMérieux and Cepheid.